Tenaya Therapeutics announces CEO Faraz Ali's participation in upcoming investor conferences on heart disease therapies.
Quiver AI Summary
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company focused on developing therapies for heart disease, announced that CEO Faraz Ali will participate in multiple investor and industry conferences in October. Ali will join a panel discussion on emerging trends in cell and gene therapy at the Cell & Gene Meeting on the Mesa on October 6, and will present at the Chardan Annual Genetic Medicines Conference on October 21, discussing in vivo gene therapies for genetic cardiac diseases. The live webcast of the latter session will be available on Tenaya's website, along with an archived replay for 30 days. Tenaya is actively developing gene therapies aimed at specific genetic heart diseases and has a range of innovative treatments in its pipeline.
Potential Positives
- Participation in prominent industry conferences enhances visibility and credibility for Tenaya Therapeutics in the biotechnology sector.
- CEO Faraz Ali's involvement in discussions on emerging trends and opportunities in cell and gene therapy highlights the company's commitment to innovation and leadership in the field.
- The presentation of Tenaya’s specific gene therapies for cardiac diseases demonstrates progress in addressing significant health challenges, potentially attracting investor interest.
- Availability of live webcasts and archives for the discussions indicates a commitment to transparency and investor engagement.
Potential Negatives
- None
FAQ
What conferences will Tenaya Therapeutics be attending in October 2025?
Tenaya Therapeutics will participate in the Cell & Gene Meeting on the Mesa and Chardan Annual Genetic Medicines Conference.
Who is the CEO of Tenaya Therapeutics?
Faraz Ali is the Chief Executive Officer of Tenaya Therapeutics.
What is Tenaya Therapeutics' mission?
Tenaya Therapeutics aims to discover, develop, and deliver potentially curative therapies for heart disease.
Where can I find the webcast of Tenaya's conference presentation?
The live webcast can be accessed from the Investors section of Tenaya’s website.
What gene therapies is Tenaya currently developing?
Tenaya is developing TN-201 for HCM and TN-401 for ARVC as gene therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TNYA Insider Trading Activity
$TNYA insiders have traded $TNYA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $TNYA stock by insiders over the last 6 months:
- FARAZ ALI (Chief Executive Officer) has made 0 purchases and 4 sales selling 17,722 shares for an estimated $19,621.
- WHITTEMORE TINGLEY (Chief Medical Officer) has made 0 purchases and 4 sales selling 7,990 shares for an estimated $7,631.
- TOMOHIRO HIGA (SVP, Finance) has made 0 purchases and 4 sales selling 4,352 shares for an estimated $4,326.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TNYA Hedge Fund Activity
We have seen 45 institutional investors add shares of $TNYA stock to their portfolio, and 61 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CASDIN CAPITAL, LLC removed 6,371,002 shares (-94.6%) from their portfolio in Q2 2025, for an estimated $3,893,956
- WOODLINE PARTNERS LP removed 5,916,167 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,615,961
- BLACKROCK, INC. removed 2,523,802 shares (-48.0%) from their portfolio in Q2 2025, for an estimated $1,542,547
- JPMORGAN CHASE & CO removed 2,258,512 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,380,402
- VR ADVISER, LLC removed 1,555,556 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $950,755
- AQR CAPITAL MANAGEMENT LLC added 966,569 shares (+124.6%) to their portfolio in Q2 2025, for an estimated $590,766
- STATE STREET CORP removed 915,431 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $559,511
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TNYA Analyst Ratings
Wall Street analysts have issued reports on $TNYA in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Chardan Capital issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $TNYA, check out Quiver Quantitative's $TNYA forecast page.
$TNYA Price Targets
Multiple analysts have issued price targets for $TNYA recently. We have seen 2 analysts offer price targets for $TNYA in the last 6 months, with a median target of $7.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $5.0 on 09/02/2025
- Geulah Livshits from Chardan Capital set a target price of $9.0 on 08/07/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in the following October investor and industry conferences. Details are below:
Cell & Gene Meeting on the Mesa
Date: Monday, October 6
Time: 8:00 AM MT – 9:00 AM MT
Format: Panel Discussion
Title: Future Horizons: Emerging Trends and Opportunities in Cell and Gene Therapy Development
Date: Monday, October 6
Time: 12:00 PM MT – 12:15 PM MT
Format: Company Presentation
Chardan Annual Genetic Medicines Conference
Date: Tuesday, October 21
Time: 12:00 PM ET – 12:40 PM ET
Format: Panel Discussion
Title: In Vivo Gene Therapies for Genetic Cardiac Diseases
The live webcast of the In Vivo Gene Therapies for Genetic Cardiac Diseases Panel Discussion may be accessed from the Investors section of Tenaya’s website . An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for
MYBPC3
-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for
PKP2
-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit
www.tenayatherapeutics.com
.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
[email protected]
Investors
Anne-Marie Fields
Precision AQ
[email protected]
